Minghui Pharmaceutical (hangzhou) Ltd
Clinical trials sponsored by Minghui Pharmaceutical (hangzhou) Ltd, explained in plain language.
-
New antibody drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called MHB039A, a bispecific antibody, in 196 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective. Participants receive the drug and are monitored for side effects and t…
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New Antibody-Drug conjugate targets advanced solid tumors in early trial
Disease control OngoingThis study tests a new drug called MHB036C, an antibody-drug conjugate, in 200 adults with advanced solid tumors. The trial has two phases: first to find the safest dose, then to see how well it works. Researchers will monitor side effects and measure drug levels in the blood.
Phase: PHASE1, PHASE2 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC